{"id":72815,"date":"2025-01-08T10:00:14","date_gmt":"2025-01-08T09:00:14","guid":{"rendered":"https:\/\/www.embl.org\/news\/?p=72815"},"modified":"2025-10-27T14:17:22","modified_gmt":"2025-10-27T13:17:22","slug":"12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research","status":"publish","type":"post","link":"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/","title":{"rendered":"New frontiers in childhood cancer research"},"content":{"rendered":"\n

Acute lymphoblastic leukaemia (ALL) is the predominant type of cancer in children. It affects one in three children with cancer.\u00a0\u00a0<\/p>\n\n\n\n

T-cell acute lymphoblastic leukaemia (T-ALL) is particularly challenging, as the chances of survival after a relapse are unfortunately extremely low, and approximately 20% of young patients will experience relapse. To address this challenge, Julia Costea, a predoctoral fellow in EMBL\u2019s Korbel group, is leading innovative research to uncover why some T-ALL cases resist treatment.<\/p>\n\n\n\n

\n
\n

\n Recognising philanthropic support <\/h3>\n

For five decades, EMBL has thrived as a global hub for cutting-edge molecular biology research, training, and services. Open collaboration has been and continues to be at the very heart of our achievements, illustrated through a rich tapestry of partnerships woven with like-minded institutions and individuals.

\r\n\r\nWith our \u201812 moments of philanthropy\u2019 series during our 50th anniversary year, we have wanted to express our deep gratitude towards individuals, foundations, and other supporters who have made a difference to EMBL through their vision and generosity. Each gift \u2013 whether small or large in financial terms \u2013 has helped advance science and nurture the scientists of the future in exemplary ways, illuminating the power of giving.\r\n

\r\nIn our final 12th \u2018moment of philanthropy\u2019, we shine a light on how a donation from the <\/span>Athenaeum Dietrich G\u00f6tze Stiftung<\/b> fuels impactful research by providing a fertile ground for new insights into the mechanisms of childhood cancer relapse.\u00a0<\/span><\/span><\/span><\/p>\n <\/div>\n<\/article>\n\n\n\n\n

A Heidelberg-based foundation known for supporting important scientific initiatives like this has helped advance this research. Started by Prof. Dietrich G\u00f6tze, a renowned immunologist and publisher, the Athenaeum Dietrich G\u00f6tze Stiftung recognised that it could leapfrog this research through generous support.<\/p>\n\n\n\n

Along with Prof. Andreas Kulozik, Director of the Department of Hematology\/Oncology at Heidelberg University Hospital, and his research group, EMBL\u2019s Korbel group scientists have worked together as part of the Molecular Medicine Partnership Unit (MMPU) to study the unique biology of relapsed T-ALL, using advanced single-cell sequencing technologies. <\/p>\n\n\n\n

This study\u2019s objectives are to develop tools that better predict relapse risk and to guide the creation of new treatment strategies that target these resistant cells. They hope this work will improve outcomes for children with T-ALL.<\/p>\n\n\n\n

By examining thousands of individual leukemic cells, the scientists have identified a small group of specialised cells possibly responsible for treatment resistance. These cells mimic healthy stem cells, and the researchers therefore refer to them as \u2018stem-like\u2019 T-ALL cells. Like healthy stem cells, they remain in a dormant state. The researchers identified that this predominantly dormant characteristic is exploited by T-ALL during chemotherapy; while other cancer cells are targeted, the stem-like cells remain untouched, potentially causing the T-ALL to return.<\/p>\n\n\n\n

The researchers also found specific markers in these cells, including proteins that help them avoid natural cell death. These so-called \u2018anti-apoptotic proteins\u2019 are important for the survival of the resistant cells. While the team has not yet tested treatments, there is hope that drugs targeting these proteins could eliminate these cells and prevent relapses \u2013 a promising avenue for future research.<\/p>\n\n\n\n

Reflecting on the importance of funding, Costea expressed her gratitude. \u201c<\/em>The generous support from the Athenaeum Stiftung has been pivotal for my PhD project.\u201d <\/em><\/p>\n\n\n\n

By understanding what makes these cells resistant to treatment, the team hopes to create better tools to predict relapses and design more effective therapies. This collaborative work between EMBL and Heidelberg University Hospital is paving the way for new approaches to hopefully improve outcomes for children with leukaemia.<\/p>\n\n\n\n

They are only at the start of their mission, but the Athenaeum Dietrich G\u00f6tze Stiftung provided the \u2018rocket fuel\u2019 with its generous support.<\/p>\n\n\n\n

\u201cA project like this is both significant, but also challenging,\u201d Costea said. \u201cThis support, however, has made an important difference to the project, enabling us to expand the patient cohort and broaden our studies. This has helped us get a better understanding of certain identified markers of those stem-like cells and assess whether they can be targeted for treatment.\u201d<\/p>\n\n\n\n

Prof. Jan Korbel, EMBL Group Leader and Head of Data Science, also stressed the invaluable impact the foundation\u2019s support has made. \u201cThis moment of philanthropy serves as a powerful reminder that together science and generosity can forge a future where, thanks to research, even the most challenging diseases might one day become surmountable.\u201d <\/p>\n\n\n\n

Our \u201812 moments of philanthropy\u2019 series in the context of EMBL\u2019s 50th anniversary ends with this article, but world-class research is ongoing at EMBL. If you would like to be an EMBL supporter and become part of our mission, <\/em><\/strong>click here<\/em><\/strong><\/a> to learn of other specific funding opportunities!<\/em><\/strong><\/p>\n\n\n\n

\n\n\n\n

Neue Horizonte in der Kinderkrebsforschung<\/h1>\n\n\n\n

Philanthropie f\u00f6rdert Entdeckungen, um Leuk\u00e4mie und deren Rezidive bei Kindern besser zu verstehen<\/h2>\n\n\n\n

Akute lymphoblastische Leuk\u00e4mie (ALL) ist die h\u00e4ufigste Krebsart bei Kindern \u2013 sie betrifft jedes dritte Kind mit Krebs. T-Zell-akute lymphoblastische Leuk\u00e4mie (T-ALL) stellt eine besondere Herausforderung dar, da die \u00dcberlebenschancen nach einem R\u00fcckfall \u00e4u\u00dferst gering sind. Etwa 20 % der jungen Patienten erleiden einen R\u00fcckfall. Um dieser Herausforderung zu begegnen, verfolgt Julia Costea, eine Doktorandin in der Korbel-Gruppe am EMBL, ein Projekt, um zu verstehen, warum einige T-ALL-F\u00e4lle resistent gegen\u00fcber Behandlungen sind.<\/p>\n\n\n\n

\n
\n

\n Dank an unsere F\u00f6rderer <\/h3>\n

Im Verlauf von f\u00fcnf Jahrzehnten hat sich das EMBL als globales Zentrum f\u00fcr molekularbiologische Spitzenforschung, Services und Dienstleistungen etabliert. Offene Zusammenarbeit ist das Herzst\u00fcck unserer Errungenschaften, veranschaulicht durch ein reiches Geflecht von Partnerschaften, die mit gleichgesinnten Institutionen und Individuen gekn\u00fcpft wurden.

\r\n\r\nMit unserer Reihe \u201e12 Momente der Philanthropie\u201c im Jahr unseres 50-j\u00e4hrigen Bestehens m\u00f6chten wir Einzelpersonen, Stiftungen und anderen Unterst\u00fctzenden, die durch ihre Vision und Gro\u00dfz\u00fcgigkeit einen Unterschied f\u00fcr das EMBL gemacht haben, unsere tiefe Dankbarkeit ausdr\u00fccken. Jede Spende – ob klein oder gro\u00df – hat dazu beigetragen, die Wissenschaft voranzubringen und die Wissenschaftler und Wissenschaftlerinnen der Zukunft auf inspirierende Weise zu f\u00f6rdern und die Kraft des Gebens zu verk\u00f6rpern.

\r\n\r\nIn unserem zw\u00f6lften und letzten \u201eMoment der Philanthropie\u201c in dieser Serie richten wir den Blick darauf, wie eine Spende der Athenaeum Dietrich G\u00f6tze Stiftung<\/b> wegweisende Forschung erm\u00f6glicht, die Grundlagen zum Verst\u00e4ndnis von Rezidiven bei Leuk\u00e4mien im Kindesalter schafft.<\/span><\/p>\n <\/div>\n<\/article>\n\n\n\n\n

Die Athenaeum Dietrich G\u00f6tze Stiftung, gegr\u00fcndet von Prof. Dietrich G\u00f6tze, einem renommierten Immunologen und Verleger, erkannte das Potenzial, diese Forschung durch gro\u00dfz\u00fcgige Unterst\u00fctzung voranzubringen.<\/p>\n\n\n\n

Zusammen mit Prof. Andreas Kulozik, dem Direktor der Abteilung H\u00e4matologie\/Onkologie des Universit\u00e4tsklinikums Heidelberg, und seiner Forschungsgruppe arbeiten die Forscher der Korbel-Gruppe im Rahmen der Molecular Medicine Partnership Unit (MMPU) daran, die Biologie der rezidivierenden T-ALL zu untersuchen, indem sie fortschrittliche Einzelzell-Sequenzierungstechnologien nutzen.<\/p>\n\n\n\n

Ziel dieser Forschung ist einerseits, Werkzeuge zu entwickeln, die das R\u00fcckfallrisiko besser vorhersagen, und dar\u00fcber hinaus neue Behandlungsstrategien zu erarbeiten, die resistente Zellen gezielt angreifen. Das Forscherteam hofft, mit dieser Arbeit die Behandlungsergebnisse f\u00fcr Kinder mit T-ALL zu verbessern.<\/p>\n\n\n\n

Durch die Untersuchung von Tausenden einzelner leuk\u00e4mischer Zellen haben die Wissenschaftler:innen eine kleine Gruppe spezialisierter Zellen identifiziert, die m\u00f6glicherweise f\u00fcr die Behandlungsresistenz verantwortlich sind. Diese Zellen ahmen gesunde Stammzellen nach und wurden daher von dem Forschungsteam als \u201estammzell\u00e4hnliche\u201c T-ALL-Zellen bezeichnet. Wie gesunde Stammzellen bleiben sie in einem Ruhezustand. Es konnte festgestellt werden, dass dieser vorwiegend ruhende Zustand von T-ALL w\u00e4hrend der Chemotherapie ausgenutzt wird: W\u00e4hrend andere Krebszellen angegriffen werden, bleiben die stammzell\u00e4hnlichen Zellen unber\u00fchrt, was m\u00f6glicherweise dazu f\u00fchrt, dass die T-ALL zur\u00fcckkehrt.<\/p>\n\n\n\n

Es wurden auch spezifische Marker in diesen Zellen entdeckt, darunter Proteine, die ihnen helfen, den nat\u00fcrlichen Zelltod zu vermeiden. Diese sogenannten \u201eanti-apoptotischen Proteine\u201c sind entscheidend f\u00fcr das \u00dcberleben dieser resistenten Zellen. Obwohl das Team noch keine Behandlungen getestet hat, besteht die Hoffnung, dass Medikamente, die auf diese Proteine abzielen, diese Zellen eliminieren und R\u00fcckf\u00e4lle verhindern k\u00f6nnten \u2013 ein vielversprechender Ansatz f\u00fcr zuk\u00fcnftige Forschung.<\/p>\n\n\n\n

Julia Costea bringt ihre Dankbarkeit zum Ausdruck: \u201eDie gro\u00dfz\u00fcgige Unterst\u00fctzung der Athenaeum Stiftung war entscheidend f\u00fcr mein Promotionsprojekt.\u201c Durch das Verst\u00e4ndnis dessen, was diese Zellen resistent gegen Behandlungen macht, hofft das Team, bessere Werkzeuge zur Vorhersage von R\u00fcckf\u00e4llen zu entwickeln und effektivere Therapien zu gestalten. Diese Zusammenarbeit zwischen EMBL und dem Universit\u00e4tsklinikum Heidelberg ebnet den Weg f\u00fcr neue Ans\u00e4tze, um hoffentlich die Behandlungsergebnisse f\u00fcr Kinder mit Leuk\u00e4mie zu verbessern. Sie befinden sich noch am Anfang ihrer Mission, doch die Athenaeum Dietrich G\u00f6tze Stiftung hat mit ihrer gro\u00dfz\u00fcgigen Unterst\u00fctzung den n\u00f6tigen Antrieb gegeben. <\/p>\n\n\n\n


\u201eEin Projekt wie dieses ist sowohl bedeutsam als auch herausfordernd\u201c, sagte Costea. \u201eDiese Unterst\u00fctzung hat einen wichtigen Unterschied f\u00fcr das Projekt gemacht, indem sie uns erm\u00f6glicht hat, die Patientenkohorte zu erweitern und unsere Studien zu vertiefen. Dadurch konnten wir ein besseres Verst\u00e4ndnis bestimmter Marker der stammzell\u00e4hnlichen Leuk\u00e4miezellen gewinnen und bewerten, ob sie in Zukunft gezielt behandelt werden k\u00f6nnen.\u201c<\/p>\n\n\n\n

Prof. Jan Korbel, EMBL-Gruppenleiter und Head of Data Science, betonte ebenfalls den unsch\u00e4tzbaren Einfluss der Unterst\u00fctzung der Stiftung: \u201eDieser Moment der Philanthropie zeigt eindrucksvoll, dass Wissenschaft und Gro\u00dfz\u00fcgigkeit gemeinsam eine Zukunft gestalten k\u00f6nnen, in der die Forschung auch f\u00fcr schwierigste Krankheiten neue L\u00f6sungen finden kann.\u201c<\/p>\n\n\n\n

Unsere Serie \u201e12 Momente der Philanthropie\u201c im Rahmen des 50-j\u00e4hrigen Jubil\u00e4ums des EMBL endet mit diesem Artikel, aber die Weltklasse-Forschung am EMBL geht weiter. Wenn auch Sie das EMBL unterst\u00fctzen und Teil unserer Mission werden m\u00f6chten, w\u00fcrden wir uns sehr freuen von Ihnen zu h\u00f6ren.<\/a><\/em><\/strong><\/p>\n\n\n\n\n","protected":false},"excerpt":{"rendered":"

In our final 12th \u2018moment of philanthropy\u2019, we shine a light on how a donation from the Athenaeum Dietrich G\u00f6tze Stiftung fuels impactful EMBL research that aims to better understand treatment-resistant childhood leukaemia.<\/p>\n","protected":false},"author":16,"featured_media":72825,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[17595],"tags":[38,17289,796,17335,13072],"embl_taxonomy":[5802],"class_list":["post-72815","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-connections","tag-cancer","tag-embl50","tag-ord","tag-philanthropy-matters","tag-support-embl","embl_taxonomy-support-embl"],"acf":{"vfwp-news_embl_taxonomy":[5802],"featured":true,"show_featured_image":false,"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"article_intro":"

Philanthropy drives discovery to better understand childhood leukaemia and relapse<\/p>\n","related_links":[{"link_description":"Support EMBL","link_url":"https:\/\/www.embl.org\/about\/info\/support\/"}],"source_article":false,"in_this_article":false,"press_contact":"None","article_translations":[{"translation_language":"Deutsch","translation_anchor":"#de"}],"languages":""},"embl_taxonomy_terms":[{"uuid":"a:3:{i:0;s:36:\"302cfdf7-365b-462a-be65-82c7b783ebf7\";i:1;s:36:\"bc1eaadd-1f50-4140-8e9b-e58fc33a39fc\";i:2;s:36:\"69e1d012-360d-4754-bf0f-9e1185643e9f\";}","parents":[],"name":["Support EMBL"],"slug":"support-embl","description":"What > About EMBL > Support EMBL"}],"yoast_head":"\nNew frontiers in childhood cancer research | EMBL<\/title>\n<meta name=\"description\" content=\"The Athenaeum Dietrich G\u00f6tze Stiftung fuels impactful EMBL research that aims to better understand treatment-resistant childhood leukaemia.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New frontiers in childhood cancer research | EMBL\" \/>\n<meta property=\"og:description\" content=\"The Athenaeum Dietrich G\u00f6tze Stiftung fuels impactful EMBL research that aims to better understand treatment-resistant childhood leukaemia.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/\" \/>\n<meta property=\"og:site_name\" content=\"EMBL\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/embl.org\/\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-08T09:00:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-27T13:17:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/PhD-lunch-072024-54-wp.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1000\" \/>\n\t<meta property=\"og:image:height\" content=\"600\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Guest author(s)\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@embl\" \/>\n<meta name=\"twitter:site\" content=\"@embl\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Guest author(s)\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/\"},\"author\":{\"name\":\"Guest author(s)\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/b4d9366b2ebe691c4015c64c3619205b\"},\"headline\":\"New frontiers in childhood cancer research\",\"datePublished\":\"2025-01-08T09:00:14+00:00\",\"dateModified\":\"2025-10-27T13:17:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/\"},\"wordCount\":1265,\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/PhD-lunch-072024-54-wp.jpg\",\"keywords\":[\"cancer\",\"embl50\",\"ord\",\"philanthropy matters\",\"support embl\"],\"articleSection\":[\"Connections\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/\",\"url\":\"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/\",\"name\":\"New frontiers in childhood cancer research | EMBL\",\"isPartOf\":{\"@id\":\"https:\/\/www.embl.org\/news\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/PhD-lunch-072024-54-wp.jpg\",\"datePublished\":\"2025-01-08T09:00:14+00:00\",\"dateModified\":\"2025-10-27T13:17:22+00:00\",\"description\":\"The Athenaeum Dietrich G\u00f6tze Stiftung fuels impactful EMBL research that aims to better understand treatment-resistant childhood leukaemia.\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/#primaryimage\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/PhD-lunch-072024-54-wp.jpg\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/PhD-lunch-072024-54-wp.jpg\",\"width\":1000,\"height\":600,\"caption\":\"Julia Costea presents her scientific project at the Friends of EMBL PhD Lunch in July 2024. Credit: Massimo del Prete\/EMBL\"},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.embl.org\/news\/#website\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"name\":\"European Molecular Biology Laboratory News\",\"description\":\"News from the European Molecular Biology Laboratory\",\"publisher\":{\"@id\":\"https:\/\/www.embl.org\/news\/#organization\"},\"alternateName\":\"EMBL News\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.embl.org\/news\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.embl.org\/news\/#organization\",\"name\":\"European Molecular Biology Laboratory\",\"alternateName\":\"EMBL\",\"url\":\"https:\/\/www.embl.org\/news\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"contentUrl\":\"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png\",\"width\":300,\"height\":144,\"caption\":\"European Molecular Biology Laboratory\"},\"image\":{\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/embl.org\/\",\"https:\/\/x.com\/embl\",\"https:\/\/www.instagram.com\/embl_org\/\",\"https:\/\/www.linkedin.com\/company\/15813\/\",\"https:\/\/www.youtube.com\/user\/emblmedia\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/b4d9366b2ebe691c4015c64c3619205b\",\"name\":\"Guest author(s)\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/300b9a1d66050ae03eaeb99869c6ebb30f5184b9468e92a2b3e7d28bc9cf742d?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/300b9a1d66050ae03eaeb99869c6ebb30f5184b9468e92a2b3e7d28bc9cf742d?s=96&d=mm&r=g\",\"caption\":\"Guest author(s)\"},\"description\":\"Guest author(s)\",\"url\":\"https:\/\/www.embl.org\/news\/author\/guest-author\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New frontiers in childhood cancer research | EMBL","description":"The Athenaeum Dietrich G\u00f6tze Stiftung fuels impactful EMBL research that aims to better understand treatment-resistant childhood leukaemia.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/","og_locale":"en_US","og_type":"article","og_title":"New frontiers in childhood cancer research | EMBL","og_description":"The Athenaeum Dietrich G\u00f6tze Stiftung fuels impactful EMBL research that aims to better understand treatment-resistant childhood leukaemia.","og_url":"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/","og_site_name":"EMBL","article_publisher":"https:\/\/www.facebook.com\/embl.org\/","article_published_time":"2025-01-08T09:00:14+00:00","article_modified_time":"2025-10-27T13:17:22+00:00","og_image":[{"width":1000,"height":600,"url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/PhD-lunch-072024-54-wp.jpg","type":"image\/jpeg"}],"author":"Guest author(s)","twitter_card":"summary_large_image","twitter_creator":"@embl","twitter_site":"@embl","twitter_misc":{"Written by":"Guest author(s)","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/#article","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/"},"author":{"name":"Guest author(s)","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/b4d9366b2ebe691c4015c64c3619205b"},"headline":"New frontiers in childhood cancer research","datePublished":"2025-01-08T09:00:14+00:00","dateModified":"2025-10-27T13:17:22+00:00","mainEntityOfPage":{"@id":"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/"},"wordCount":1265,"publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"image":{"@id":"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/PhD-lunch-072024-54-wp.jpg","keywords":["cancer","embl50","ord","philanthropy matters","support embl"],"articleSection":["Connections"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/","url":"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/","name":"New frontiers in childhood cancer research | EMBL","isPartOf":{"@id":"https:\/\/www.embl.org\/news\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/#primaryimage"},"image":{"@id":"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/#primaryimage"},"thumbnailUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/PhD-lunch-072024-54-wp.jpg","datePublished":"2025-01-08T09:00:14+00:00","dateModified":"2025-10-27T13:17:22+00:00","description":"The Athenaeum Dietrich G\u00f6tze Stiftung fuels impactful EMBL research that aims to better understand treatment-resistant childhood leukaemia.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/connections\/12-moments-of-philanthropy-12-new-frontiers-in-childhood-cancer-research\/#primaryimage","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/PhD-lunch-072024-54-wp.jpg","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/PhD-lunch-072024-54-wp.jpg","width":1000,"height":600,"caption":"Julia Costea presents her scientific project at the Friends of EMBL PhD Lunch in July 2024. Credit: Massimo del Prete\/EMBL"},{"@type":"WebSite","@id":"https:\/\/www.embl.org\/news\/#website","url":"https:\/\/www.embl.org\/news\/","name":"European Molecular Biology Laboratory News","description":"News from the European Molecular Biology Laboratory","publisher":{"@id":"https:\/\/www.embl.org\/news\/#organization"},"alternateName":"EMBL News","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.embl.org\/news\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.embl.org\/news\/#organization","name":"European Molecular Biology Laboratory","alternateName":"EMBL","url":"https:\/\/www.embl.org\/news\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/","url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","contentUrl":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/09\/EMBL_logo_colour-1-300x144-1.png","width":300,"height":144,"caption":"European Molecular Biology Laboratory"},"image":{"@id":"https:\/\/www.embl.org\/news\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/embl.org\/","https:\/\/x.com\/embl","https:\/\/www.instagram.com\/embl_org\/","https:\/\/www.linkedin.com\/company\/15813\/","https:\/\/www.youtube.com\/user\/emblmedia\/"]},{"@type":"Person","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/b4d9366b2ebe691c4015c64c3619205b","name":"Guest author(s)","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.embl.org\/news\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/300b9a1d66050ae03eaeb99869c6ebb30f5184b9468e92a2b3e7d28bc9cf742d?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/300b9a1d66050ae03eaeb99869c6ebb30f5184b9468e92a2b3e7d28bc9cf742d?s=96&d=mm&r=g","caption":"Guest author(s)"},"description":"Guest author(s)","url":"https:\/\/www.embl.org\/news\/author\/guest-author\/"}]}},"field_target_display":"embl","field_article_language":{"value":"english","label":"English"},"fimg_url":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/PhD-lunch-072024-54-wp.jpg","featured_image_src":"https:\/\/www.embl.org\/news\/wp-content\/uploads\/2025\/01\/PhD-lunch-072024-54-wp.jpg","_links":{"self":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/72815","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/users\/16"}],"replies":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/comments?post=72815"}],"version-history":[{"count":11,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/72815\/revisions"}],"predecessor-version":[{"id":76899,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/posts\/72815\/revisions\/76899"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media\/72825"}],"wp:attachment":[{"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/media?parent=72815"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/categories?post=72815"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/tags?post=72815"},{"taxonomy":"embl_taxonomy","embeddable":true,"href":"https:\/\/www.embl.org\/news\/wp-json\/wp\/v2\/embl_taxonomy?post=72815"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}